Information de reference pour ce titreAccession Number: | 01445436-200904010-00017.
|
Author: | De Vuyst, Hugo 1; Clifford, Gary M. 1; Nascimento, Maria Claudia 1; Madeleine, Margaret M. 2; Franceschi, Silvia 1
|
Institution: | (1) International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon cedex 08, France (2) Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA
|
Title: | |
Source: | International Journal Of Cancer. 124(7):1626-1636, April 1, 2009.
|
Abstract: | This meta-analysis investigated human papillomavirus (HPV) prevalence in vulvar, vaginal and anal intraepithelial neoplasia (VIN, VAIN, AIN) grades 1-3 and carcinoma from 93 studies conducted in 4 continents and using PCR assays. Overall HPV prevalence was 67.8%, 85.3% and 40.4% among 90 VIN1, 1,061 VIN2/3 and 1,873 vulvar carcinomas; 100%, 90.1% and 69.9% among 107 VAIN1, 191 VAIN2/3 and 136 vaginal carcinomas; and 91.5%, 93.9% and 84.3% among 671 AIN1, 609 AIN2/3 and 955 anal carcinomas, respectively. HPV16 was found more frequently (>75%) and HPV18 less frequently (<10%) in HPV-positive vulvar, vaginal and anal carcinomas than in cervical carcinoma. HPV6 and 11 were common in VIN1 and AIN1, but not in VAIN1. HPV prevalence in vulvar carcinoma varied most by histological type (69.4% in warty-basaloid and 13.2% in keratinized type) and was also higher in women 60 years or younger and in studies carried out in North America. HPV prevalence in anal carcinoma was higher among women (90.8%) than men (74.9%), but no difference by gender emerged in North America. The majority of AIN2/3 derived from studies of HIV-positive individuals and/or men who have sex with men. Among AIN2/3, HIV infection was associated with higher HPV prevalence, more multiple-type infections and a relative under-representation of HPV16. In conclusion, ~40% of vulvar, 60% of vaginal and 80% of anal carcinoma may be avoided by prophylactic vaccines against HPV16/18. This proportion would be similar for the corresponding high-grade lesions of the vagina and anus, but higher for VIN2/3 (75%) than for vulvar carcinoma. (C) 2008 Wiley-Liss, Inc.
Copyright (C) 2009 John Wiley & Sons, Inc.
|
Author Keywords: | vulva; vagina; anus; carcinoma; human papillomavirus; human immunodeficiency virus; meta-analysis.
|
References: | 1. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P.Cancer incidence in five continents, vol. 9. Lyon: International Agency for Research on Cancer, 2007.
2. Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, Porter PL, Galloway DA, McDougall JK, Tamimi H. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002; 84: 263-70.
3. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101: 270-80.
4. Madeleine MM, Daling JR, Carter JJ, Wipf GC, Schwartz SM, McKnight B, Kurman RJ, Beckmann AM, Hagensee ME, Galloway DA. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst 1997; 89: 1516-23.
5. Hildesheim A, Han CL, Brinton LA, Kurman RJ, Schiller JT. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study. Obstet Gynecol 1997; 90: 748-54.
6. Madsen BS, Jensen HL, van den Brule AJ, Wohlfahrt J, Frisch M. Risk factors for invasive squamous cell carcinoma of the vulva and vagina-population-based case-control study in Denmark. Int J Cancer 2008; 122: 2827-34.
7. Grulich AE, Tvan Leeuwen M, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67.
8. Frisch M, Glimelius B, van den Brule AJ, Wohlfahrt J, Meijer CJ, Walboomers JM, Goldman S, Svensson C, Adami HO, Melbye M. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997; 337: 1350-8.
9. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004; 101: 281-8.
10. Frisch M, Melbye M, Moller H. Trends in incidence of anal cancer in Denmark. BMJ 1993; 306: 419-22.
11. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006; 107: 1018-22.
12. Joura EA, Losch A, Haider-Angeler MG, Breitenecker G, Leodolter S. Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med 2000; 45: 613-15.
13. Jones RW, Baranyai J, Stables S. Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol 1997; 90: 448-52.
14. IARC.Monographs on the evaluation of carcinogenic risks to humans, Human Papillomaviruses, vol. 90. Lyon: IARC Press, 2007.
15. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693-702.
16. Coutlee F, Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, Boyle S, Hankins C, Vezina S, Cote P, Macleod J, Voyer H, et al. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the linear array HPV genotyping test. J Clin Microbiol 2006; 44: 1998-2006.
17. Critchlow CW, Hawes SE, Kuypers JM, Goldbaum GM, Holmes KK, Surawicz CM, Kiviat NB. Effect of HIV infection on the natural history of anal human papillomavirus infection. Aids 1998; 12: 1177-84.
18. Piketty C, Darragh TM, Da Costa M, Bruneval P, Heard I, Kazatchkine MD, Palefsky JM. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003; 138: 453-9.
19. Varnai AD, Bollmann M, Griefingholt H, Speich N, Schmitt C, Bollmann R, Decker D. HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis. Int J Colorectal Dis 2006; 21: 135-42.
20. Wang C, Hawes SE, Lampinen T, Feng Q, Kiviat N. HPV prevalence and types in anal swab samples of HIV+ MSM in Seattle. PS11-09, 24th International Papillomavirus Conference and Clinical Workshop, Beijing, China; 3-9 November 2007. 236 p.
21. World Health Organisation Classification of Tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press, 2003.
22. Fenger C, Frisch M, Marti MC, Parc R. Tumours of the anal canal. In: Hamilton SR,Aaltonen LA, eds. World Health Organization classification of tumours: pathology and genetics. Tumours of the digestive system. Lyon: IARC Press, 2000: 147-55.
23. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
24. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73.
25. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621-32.
26. Goldstone SE, Winkler B, Ufford LJ, Alt E, Palefsky JM. High prevalence of anal squamous intraepithelial lesions and squamous-cell carcinoma in men who have sex with men as seen in a surgical practice. Dis Colon Rectum 2001; 44: 690-8.
27. Andersen WA, Franquemont DW, Williams J, Taylor PT, Crum CP. Vulvar squamous cell carcinoma and papillomaviruses: two separate entities? Am J Obstet Gynecol 1991; 165: 329-35.
28. Kurman RJ, Toki T, Schiffman MH. Basaloid and warty carcinomas of the vulva. Distinctive types of squamous cell carcinoma frequently associated with human papillomaviruses. Am J Surg Pathol 1993; 17: 133-45.
29. Dai M, Clifford GM, Le Calvez F, Castellsague X, Snijders PJ, Pawlita M, Herrero R, Hainaut P, Franceschi S,for the IARC Multi-center Oral Cancer Study Group. Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res 2004; 64: 468-71.
30. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-75.
31. Clifford G, Franceschi S. Members of the human papillomavirus type 18 family ([alpha]-7 species) share a common association with adenocarcinoma of the cervix. Int J Cancer 2008; 122: 1684-5.
32. SEER. Stat 6.1.4. SEER cancer incidence public-use database, 1973-2002. 4-25-0005. Bethesda, MD: Cancer Statistics Branch, National Cancer Institute, NIH, 2008.
33. Skapa P, Zamecnik J, Hamsikova E, Salakova M, Smahelova J, Jandova K, Robova H, Rob L, Tachezy R. Human papillomavirus (HPV) profiles of vulvar lesions: possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination. Am J Surg Pathol 2007; 31: 1834-43.
34. Hording U, Kringsholm B, Andreasson B, Visfeldt J, Daugaard S, Bock JE. Human papillomavirus in vulvar squamous-cell carcinoma and in normal vulvar tissues: a search for a possible impact of HPV on vulvar cancer prognosis. Int J Cancer 1993; 55: 394-6.
35. Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 2006; 108: 1361-8.
36. Sutton BC, Allen RA, Moore WE, Dunn ST. Distribution of human papillomavirus genotypes in invasive squamous carcinoma of the vulva. Mod Pathol 2008; 21: 345-54.
37. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17: 1611-22.
38. Palefsky JM. HPV infection in men. Dis Markers 2007; 23: 261-72.
39. Clifford GM, Goncalves MA, Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. Aids 2006; 20: 2337-44.
40. Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, Minkoff H, Duerr A, Massad LS, Celentano DD, Hall C, Fazzari M, Cu-Uvin S, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003; 95: 1062-71.
41. De Vuyst H, Gichangi P, Estambale B, Njuguna E, Franceschi S, Temmerman M. Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. Int J Cancer 2008; 122: 244-6.
42. Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, Haefner H, Neill S. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med 2005; 50: 807-10.
|
Language: | English.
|
Document Type: | Epidemiology.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0020-7136
|
DOI Number: | https://dx.doi.org/10.1002/ijc.2...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|